Sanofi Lovenox Patent To Return To Court
This article was originally published in The Pink Sheet Daily
Executive Summary
A lower court will reevaluate the validity of a Sanofi-Aventis patent covering its injectable antithrombotic Lovenox (enoxaparin) following a federal court of appeals ruling April 10